It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.04.16.23288642;](https://doi.org/10.1101/2023.04.16.23288642) this version posted April 24, 2023. The copyright holder for this preprint

Association Between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy

-
- 4 David D Yang^{a,b,*}, Leslie K Lee^{b,*}, James MG Tsui^c, Jonathan E Leeman^{a,b}, Katie N
- 5 Lee^{a,b}, Heather M McClure^a, Atchar Sudhyadhom^{a,b}, Christian V Guthier^{a,b}, Kent W
- 6 Mouwa,b, Neil E Martina,b, Peter F Orioa,b, Paul L Nguyena,b, Anthony V D'Amicoa,b,
- 7 Martin T King^{a,b}
-
- ^aDana-Farber Cancer Institute, Boston, MA, USA
- 10 bBrigham and Women's Hospital, Boston, MA, USA
- **CMcGill University, Montreal, Canada**
-
- *Equal contribution
-

Corresponding Author

- Martin T King
- 75 Francis St
- Boston, MA 02115
- Telephone: +1-617-732-5640
- Fax: +1-617-632-4247
- Email: Martin_King@dfci.harvard.edu
-
- Keywords: artificial intelligence; deep learning; dominant intraprostatic lesion; magnetic
- resonance imaging; PI-RADS; prostate cancer; radiomics; radiation therapy
-
- Abstract word count: 300
- Text word count: 2794 (including abstract)

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.04.16.23288642;](https://doi.org/10.1101/2023.04.16.23288642) this version posted April 24, 2023. The copyright holder for this preprint

- **Background**: Although clinical features of multi-parametric magnetic resonance
- imaging (mpMRI) have been associated with biochemical recurrence in localized
- prostate cancer, such features are subject to inter-observer variability.
- **Objective**: To evaluate whether the volume of the dominant intraprostatic lesion (DIL),
- as provided by a deep learning segmentation algorithm, could provide prognostic
- information for patients treated with definitive radiation therapy (RT).

Design, Setting, and Participants: Retrospective study of 438 patients with localized

prostate cancer who underwent an endorectal coil, high B-value, 3-Tesla mpMRI and

were treated with RT between 2010 and 2017.

Intervention: RT.

 Outcome Measurements and Statistical Analysis: Biochemical recurrence and metastasis risk, assessed with a cause-specific Cox regression and time-dependent

receiver operating characteristic analysis.

 Results and Limitations: The artificial intelligence (AI) model identified DILs with an area under the receiver operating characteristic curve (AUROC) of 0.827 at the patient level. For the 233 patients with available PI-RADS scores, with a median follow-up of

5.6 years, AI-defined DIL volume was significantly associated with biochemical failure

(adjusted hazard ratio 1.54, 95% confidence interval 1.09-2.17, p=0.014) after

adjustment for PI-RADS score. Among all 438 patients with a median follow-up of 6.9

years, the AUROC for predicting 7-year biochemical failure for AI volume (0.790) was

similar to that for an expanded National Comprehensive Cancer Network (NCCN+)

category (p=0.17). The AUROC for predicting 7-year metastasis for AI volume trended

towards being higher compared to NCCN+ categories (0.854 vs 0.769, p=0.06).

- **Conclusions**: A deep learning algorithm could identify the DIL with good performance.
- AI-defined DIL volume may be able to provide prognostic information independent of the
- NCCN+ risk group or other radiologic factors for patients with localized prostate cancer
- treated with RT.

Introduction

 of artificial intelligence (AI) algorithms for supporting the radiologist's workflow. Although the performance of AI algorithms has not been shown to match that of radiologists for the detection of clinically significant prostate cancer²², recent work suggests that deep

- learning algorithms could be used as an adjunct for assisting radiologists²³. However,
- less is known about the prognostic information provided by deep learning algorithms,
- particularly in comparison to current staging systems. The purpose of this study is to
- evaluate whether the mpMRI DIL volume, as determined by a deep learning
- s 82 segmentation algorithm²⁴, could provide prognostic information for patients with
- localized prostate cancer treated with definitive radiation therapy (RT).

Methods

Clinical datasets

Results

Assessment of AI DIL performance

Comparison of AI and reference DIL contours for sextant subset

 For the subset of 303 patients with sextant biopsies among all 3 cohorts, we did not detect a difference in AUROC values associated with AI versus reference contours for any sextant (Table S7).

Comparison of DIL volume with radiologic staging for PI-RADS subset

Discussion

 Our study demonstrates that the prostate and DIL can be accurately delineated 233 on mpMRI using nnUNet,²⁴ an out-of-the-box self-configuring deep learning segmentation algorithm. Our findings suggest that AI-determined DIL volume provides prognostic information comparable to both NCCN+ risk category and human-generated DIL volume for estimating biochemical recurrence and metastasis risk for localized prostate cancer treated with RT. Furthermore, for the subset of patients with PI-RADS 238 scores, V_{Al} was more strongly associated with biochemical failure than other mpMRI parameters, including radiologic staging and PI-RADS score. Though other studies have reported on the prognostic significance of tumor size 241 for biochemical recurrence^{8–11}, ours is among the first to show that DIL volume can be reliably obtained with an AI algorithm. This is clinically meaningful because DIL volume determination can be time-consuming and is subject to significant inter-observer 244 variability³¹. The AI algorithm, on the other hand, was able to generate the DIL volume in an efficient, automated, and standardized manner. Additionally, this work may be 246 clinically impactful as it suggests that V_{Al} could provide important prognostic information 247 even in the absence of a biopsy. With further validation, V_{AI} could have the potential to provide unique prognostic information in addition to that provided with current clinical and radiologic staging systems.

 VAI shows exceptional promise as a potential prognostic factor as it is a single, well-defined entity which may be generated in a systematic manner from mpMRI. Unlike 252 NCCN risk categories²⁵, V_{AI} does not require the presence of a systematic biopsy, which 253 may be important as MR-only biopsies are increasingly utilized⁴. Unlike radiomic

17

289

290 Table 1: Baseline clinical, radiologic, and treatment factors.

291 SV: seminal vesicles. EBRT: external beam radiation therapy. Radiologic T stage and

292 hemorrhage data were not available for the TestNoPIRADS cohort.

18

293

294 Table 2: Cox regression model for biochemical failure for the subset of 233 patients with

295 available PI-RADS scores.

296 CI: confidence interval. HR: hazard ratio. AHR: adjusted hazard ratio. SOC: standard of

297 care treatment. Ref: reference.

19

299

300 Table 3: Cox regression model for biochemical failure for all patients.

301 CI: confidence interval. HR: hazard ratio. AHR: adjusted hazard ratio. SOC: standard of

- 302 care treatment. Ref: reference. FIR: favorable intermediate-risk. UIR: unfavorable
- 303 intermediate-risk.

20

305

306 Table 4: Cox regression model for metastasis for all patients.

307 CI: confidence interval. HR: hazard ratio. AHR: adjusted hazard ratio. SOC: standard of

308 care treatment. Ref: reference. FIR: favorable intermediate-risk. UIR: unfavorable

309 intermediate-risk.

 Fig 1: Receiver operating characteristics curves for 7-year biochemical failure (a) and metastasis (b), comparing AI DIL volume (red) against reference DIL volume (blue) and NCCN+ stratification (black). Circle and triangle are points on the AI volume receiver operating characteristics curve corresponding to thresholds of 0.5 cc and 2.0 cc, respectively.

- c)
- Fig 2: Cumulative incidence curves of DIL volume intervals (0-0.4, 0.5-1.9, 2.0- cc) with
- (a) biochemical failure, (b) local failure, and (c) metastasis.

References

- 1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi- parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *The Lancet*. 2017;389(10071):815-822. doi:10.1016/S0140- 6736(16)32401-1
- 2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
- 3. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. *N Engl J Med*. 2020;382(10):917-928. doi:10.1056/NEJMoa1910038
- 4. Hugosson J, Månsson M, Wallström J, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. *N Engl J Med*. 2022;387(23):2126- 2137. doi:10.1056/NEJMoa2209454
- 5. Rajwa P, Mori K, Huebner NA, et al. The Prognostic Association of Prostate MRI PI-338 RADS[™] v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. *J Urol*. 2021;206(3):507. doi:10.1097/JU.0000000000001821
- 6. Baboudjian M, Gondran-Tellier B, Touzani A, et al. Magnetic Resonance Imaging– based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification. *Eur Urol Oncol*. Published online October 21, 2022. doi:10.1016/j.euo.2022.09.005
- 7. Rakauskas A, Peters M, Ball D, et al. The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon. *Urol Oncol Semin Orig Investig*. Published online December 21, 2022. doi:10.1016/j.urolonc.2022.10.023
- 8. Hutten R, Khouri A, Parsons M, et al. The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. *Clin Genitourin Cancer*. 2022;20(6):e453-e459. doi:10.1016/j.clgc.2022.06.010
- 9. Woo S, Han S, Kim TH, et al. Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. *Am J Roentgenol*. 2019;214(3):597-604. doi:10.2214/AJR.19.21836
- 10. Jambor I, Falagario U, Ratnani P, et al. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. *J Magn Reson Imaging*. 2020;51(4):1075-1085. doi:10.1002/jmri.26928
- 11. Stabile A, Mazzone E, Cirulli GO, et al. Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2021;4(4):519-528. doi:10.1016/j.euo.2020.11.008
- 12. Mazzone E, Gandaglia G, Ploussard G, et al. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel
- Risk Groups. *Eur Urol*. 2022;81(2):193-203. doi:10.1016/j.eururo.2021.07.027

- 13. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. *Eur Radiol*. 2012;22(4):746-757. doi:10.1007/s00330-011-2377-y 14. Costa DN, Passoni NM, Leyendecker JR, et al. Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI. *Am J Roentgenol*. 2018;210(5):1066-1072. doi:10.2214/AJR.17.18849 15. Mehralivand S, Shih JH, Harmon S, et al. A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. *Radiology*. 2019;290(3):709-719. doi:10.1148/radiol.2018181278 16. Park KJ, Kim M hyun, Kim JK. Extraprostatic Tumor Extension: Comparison of Preoperative Multiparametric MRI Criteria and Histopathologic Correlation after Radical Prostatectomy. *Radiology*. 2020;296(1):87-95. doi:10.1148/radiol.2020192133 17. Muller BG, Shih JH, Sankineni S, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. *Radiology*. 2015;277(3):741-750. doi:10.1148/radiol.2015142818 18. Rosenkrantz AB, Ginocchio LA, Cornfeld D, et al. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. *Radiology*. 2016;280(3):793-804. doi:10.1148/radiol.2016152542 19. Smith CP, Harmon SA, Barrett T, et al. Intra- and interreader reproducibility of PI- RADSv2: A multireader study. *J Magn Reson Imaging*. 2019;49(6):1694-1703. doi:10.1002/jmri.26555 20. Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. *Radiology*. 2020;296(1):76-84. doi:10.1148/radiol.2020190646 21. Panebianco V, Giganti F, Kitzing YX, et al. An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. *Insights Imaging*. 2018;9(1):87-101. doi:10.1007/s13244-017-0578-x 22. Hosseinzadeh M, Saha A, Brand P, Slootweg I, de Rooij M, Huisman H. Deep learning–assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge. *Eur Radiol*. 2022;32(4):2224- 2234. doi:10.1007/s00330-021-08320-y 23. Mehralivand S, Yang D, Harmon SA, et al. Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI. *Abdom Radiol*. 2022;47(4):1425- 1434. doi:10.1007/s00261-022-03419-2 24. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self- configuring method for deep learning-based biomedical image segmentation. *Nat Methods*. 2021;18(2):203-211. doi:10.1038/s41592-020-01008-z 25. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Cancer Netw JNCCN*. 2019;17(5):479-505. doi:10.6004/jnccn.2019.0023
- 26. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis
- of primary results from two randomised controlled phase 3 trials of the STAMPEDE

- analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). *Eur Urol*. 2022;82(5):487-498. doi:10.1016/j.eururo.2022.07.011
- 39. Chatterjee A, Turchan WT, Fan X, et al. Can Pre-treatment Quantitative Multi-
- parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate
- Cancer? *Acad Radiol*. 2022;29(7):977-985. doi:10.1016/j.acra.2021.09.012